Dec 16 (Reuters) - Foghorn Therapeutics Inc. FHTX.O:
FOGHORN THERAPEUTICS PROVIDES UPDATE ON FHD-286 CLINICAL DEVELOPMENT PROGRAM AND STRATEGIC PRIORITIES
FOGHORN THERAPEUTICS INC. - TO DISCONTINUE INDEPENDENT DEVELOPMENT OF FHD-286 FOR AML
FOGHORN THERAPEUTICS INC. - EVALUATING PARTNERSHIPS AND ISTS TO ADVANCE FHD-286
FOGHORN THERAPEUTICS INC. - TO PRIORITIZE PROPRIETARY PIPELINE AND LILLY COLLABORATION PROGRAMS
FOGHORN THERAPEUTICS INC. - PHASE 1 TRIAL OF FHD-286 SHOWED CLINICAL RESPONSES BUT DID NOT MEET THRESHOLD
Source text: ID:nGNXXnDbx
Further company coverage: FHTX.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.